DOI QR코드

DOI QR Code

Tailored Surveillance Strategies for Pancreatic Cancer in Patients with Chronic Pancreatitis

  • Haegwang Shin (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine) ;
  • Jung Wan Choe (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine)
  • 투고 : 2024.07.15
  • 심사 : 2024.08.08
  • 발행 : 2024.08.20

초록

Chronic pancreatitis, a significant risk factor for pancreatic cancer, necessitates monitoring for pancreatic cancer development. Chronic pancreatitis can be broadly categorized into hereditary and sporadic. Given the variability in the risk for pancreatic cancer based on the presence and type of genetic mutations, it is crucial to establish and be aware of guidelines for screening and surveillance tailored to each risk level. In cases of hereditary chronic pancreatitis with PRSS1 mutations, patients demonstrated a high incidence of pancreatic cancer, justifying the rationale for screening and surveillance. However, the incidence of pancreatic cancer is relatively low in hereditary chronic pancreatitis with other genetic mutations and sporadic chronic pancreatitis; thus, precise screening and periodic surveillance are not recommended. For individuals with PRSS1 mutation-related hereditary chronic pancreatitis, surveillance may be considered from the age of 40 years. While computed tomography or magnetic resonance imaging is suitable for pancreatic cancer screening, endoscopic ultrasonography is not recommended because of parenchymal inflammation, fibrosis, and calcification. However, in cases of sporadic chronic pancreatitis where various risk factors for pancreatic cancer coexist, the incidence of pancreatic cancer significantly increases. Therefore, in 5 years after the diagnosis of chronic pancreatitis, the pancreatic cancer incidence has been observed to continuously increase. In such cases, individualized screening tests and surveillance based on the patient's symptoms and specific circumstances must be considered.

키워드

참고문헌

  1. Kirkegard J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol 2017;112:1366-1372. https://doi.org/10.1038/ajg.2017.218
  2. Greenhalf W, Levy P, Gress T, et al. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology 2020;20:910-918. https://doi.org/10.1016/j.pan.2020.05.011
  3. Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004;2:252-261. https://doi.org/10.1016/s1542-3565(04)00013-8
  4. Lowenfels AB, Maisonneuve P, Dimagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442-446. https://doi.org/10.1093/jnci/89.6.442
  5. Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology 2020;159:358-362. https://doi.org/10.1053/j.gastro.2020.03.088
  6. Munigala S, Subramaniam DS, Subramaniam DP, Burroughs TE, Conwell DL, Sheth SG. Incidence and risk of pancreatic cancer in patients with a new diagnosis of chronic pancreatitis. Dig Dis Sci 2022;67:708-715. https://doi.org/10.1007/s10620-021-06886-7
  7. Kim HS, Gweon TG, Park SH, Kim TH, Kim CW, Chang JH. Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance. Sci Rep 2023;13:106. https://doi.org/10.1038/s41598-022-26411-8